Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U. Milani P, et al. Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. Blood. 2018. PMID: 30108065 Free article. No abstract available.
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.
Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO. Bochtler T, et al. Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200. Blood Adv. 2018. PMID: 30327369 Free PMC article.
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.
Dreger P, Dietrich S, Schubert ML, Selberg L, Bondong A, Wegner M, Stadtherr P, Kimmich C, Kosely F, Schmitt A, Pavel P, Liebers N, Luft T, Hegenbart U, Radujkovic A, Ho AD, Müller-Tidow C, Schmitt M. Dreger P, et al. Blood Adv. 2020 Dec 22;4(24):6157-6168. doi: 10.1182/bloodadvances.2020003036. Blood Adv. 2020. PMID: 33351108 Free PMC article.
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Kimmich CR, Terzer T, Benner A, Hansen T, Carpinteiro A, Dittrich T, Veelken K, Jauch A, Huhn S, Basset M, Goldschmidt H, Müller-Tidow C, Schönland SO, Hegenbart U. Kimmich CR, et al. Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33844864 Free article. No abstract available.
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M, Kimmich CR, Schreck N, Krzykalla J, Dittrich T, Veelken K, Goldschmidt H, Seckinger A, Hose D, Jauch A, Müller-Tidow C, Benner A, Hegenbart U, Schönland SO. Basset M, et al. Br J Haematol. 2021 Oct;195(2):230-243. doi: 10.1111/bjh.17685. Epub 2021 Aug 3. Br J Haematol. 2021. PMID: 34341985
505 results